Wave Life Sciences

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

Cambridge, US
Size (employees)
41 (est)
Wave Life Sciences was founded in 2012 and is headquartered in Cambridge, US

Wave Life Sciences Office Locations

Wave Life Sciences has an office in Cambridge
Cambridge, US (HQ)
733 Concord Ave

Wave Life Sciences Data and Metrics

Wave Life Sciences Financial Metrics

Wave Life Sciences's revenue was reported to be $1.5 m in FY, 2016 which is a 877% increase from the previous period.

Revenue (FY, 2016)

1.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(55.4 m)

EBIT (FY, 2016)

(55.3 m)

Market capitalization (27-Jun-2017)

566.8 m

Closing share price (27-Jun-2017)


Cash (31-Dec-2016)

150.3 m
Wave Life Sciences's current market capitalization is $566.8 m.
USDFY, 2015FY, 2016


152 k1.5 m

Revenue growth, %


R&D expense

9.1 m40.8 m

General and administrative expense

10.4 m16 m

Operating expense total

19.5 m56.8 m


(19.3 m)(55.3 m)

EBIT margin, %


Interest expense

86 k337 k

Interest income

86 k337 k

Income tax expense

(44 k)(616 k)

Net Income

(19.2 m)(55.4 m)
USDFY, 2015FY, 2016


161.2 m150.3 m

Accounts Receivable

200 k


146 k1.5 m

Current Assets

161.4 m152 m


2.8 m8.6 m

Total Assets

165.4 m164.8 m

Accounts Payable

2.8 m4.9 m

Current Liabilities

3.8 m12.2 m

Non-Current Liabilities

241 k9.9 m

Total Liabilities

4.1 m22.1 m

Additional Paid-in Capital

3.2 m10 m

Retained Earnings

(35.1 m)(90.5 m)

Total Equity

153.5 m134.9 m

Financial Leverage

1.1 x1.2 x
USDFY, 2015FY, 2016

Net Income

(19.2 m)(55.4 m)

Depreciation and Amortization

594 k784 k

Accounts Receivable

193 k193 k


(63 k)(1.3 m)

Accounts Payable

1.6 m3.4 m

Cash From Operating Activities

(12.5 m)(31.9 m)

Purchases of PP&E

(1.9 m)(5.6 m)

Cash From Investing Activities

(2.9 m)(8.2 m)

Cash From Financing Activities

175.6 m29.1 m

Interest Paid

86 k29 k
USDY, 2016


36.2 k

Financial Leverage

1.2 x

Wave Life Sciences Operating Metrics

FY, 2016

Phase II Trials


Patents Issued


Patents Pending


Phase I Trials


Wave Life Sciences Market Value History

Wave Life Sciences Online and Social Media Presence

Wave Life Sciences Company Life and Culture

You may also be interested in